“…Also, neither clinical efficacy of RIT did appear to be compromised, nor toxicity increased. 20 Similarly, in 2 trials using rituximab + chemotherapy combination therapy before 90 Y-IT application, 28,29 a significant rate of conversion from partial response (PR) to complete response (CR) was observed, again indicating that prior rituximab therapy does not hamper RIT. Since 2002, 90 Y-IT is approved in the United States (US) for patients with CD20+FL or transformed B-cell NHL, refractory to or relapsed after rituximab.…”